Clarify drives demonstrable impact for commercial teams
More patients with a rare heart condition were identified by uncovering patients who were most likely mis-diagnosed
More scripts of a rare disease treatment were written by HCPs that Clarify scored as high-opportunity
Patients identified at high risk of non-adherence to infusion therapy by using social determinants of health data
Life sciences analytics, queryable in seconds
Enhance your brand’s launch and in-market performance with our real-world commercial analytics. They extract the micro-level detail you need to compete differently. You can sub-segment patients by any inclusion and exclusion criteria, rank HCP based on therapy-specific factors, and track share versus your competitors at the patient segment level.
Whether you are assessing the potential of a partnership deal or exploring a new market opportunity, this analytics software gives you the inputs you need to gauge true value, in seconds. Using its self-service capabilities, you can build precise cohorts, slice and dice them by clinical and non-clinical characteristics, and understand treating HCPs.
Evaluating your protocol against real-world data can go a long way to ensuring you can recruit the right patients to meet your study endpoints. Our advanced analytics software is configurable to any therapeutic area, and lets you optimize your protocol based on real-world patient eligibility and advanced scoring of site investigators.
Pfizer and Clarify talk data strategies for commercialization
Pfizer and Clarify Health sat down with HLTH to talk about creating data-driven value stories for new therapies. Hear what Bhash Parasuraman, Vice President and BU Lead, Rare Disease Patient & Health Impact, Pfizer and Manisha Gulati, Chief Operating Officer, Clarify Health have to say.